ICB treatment allows T cells to escape the inhibitory effects of tumor cells when the PD-1/PD-L1 pathway is blocked, and the anti-tumor immune response mediated by T cells is therefore restored (Figure 1). The gene discussed is CD274; the disease is neoplasm.